Guidelines for Therapeutic Drug Monitoring of Imatinib

William Clarke
The Johns Hopkins University School of Medicine
USA

Extended abstract:

“Imatinib mesylate (Gleevec®, Glivec®) is a potent inhibitor of BCR-ABL tyrosine kinase, and is widely used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) – it has now become a standard of care in treatment of these diseases. It has demonstrated significant clinical efficacy for both CML and GIST, producing durable responses and prolonged survival; however, it has significant pharmacokinetic variability and for patients on long-term therapy, there are issues with non-adherence. Against this backdrop, there have been many studies suggesting the utility of TDM in imatinib therapy, and the TDM in Oncology Scientific Committee of IATDMCT is developing a consensus guideline for best practices in this area. This symposium will summarize the pertinent literature regarding imatinib pharmacology and TDM, and will present the preliminary consensus guidelines developed by the scientific committee.”